Genetics of Tumor Suppression


Franck Toledo Team Leader Tel:

The p53 pathway is altered in most, if not all, tumours. In more than half of human cancers, the p53 gene is mutated and, in the other half, the p53 protein is inactivated, often by overexpression of its specific inhibitors MDM2 and MDM4.

A better understanding of the pathways that regulate p53 could lead to development of new and broadly applicable anti-cancer strategies. Our group is using mouse models to gain a better understanding of the regulation of p53.

Much of what we know about the regulation of p53 results from biochemical studies and analyses relying on transfection of expression plasmids into cells in culture. In recent years, studies of several mouse models carrying targeted p53 mutations revealed significant differences between the in vivo data and those obtained by earlier in vitro approaches. For example, we found that mutation of threonine and proline residues in p53’s proline rich domain (PRD), which were thought to be essential for regulation of the protein, did not significantly affect the transactivation or tumor suppressor function of p53 in the mouse – a finding that may explain the sequence variability of the PRD in evolution.

Figure 1 : Modèle de régulation de p53 basé sur une complémentarité fonctionelle entre Mdm2 et Mdm4.
Figure 1 : A model for co-operative control of p53 by Mdm2 and Mdm4 : Mdm2 promotes the degradation of p53, whereas Mdm4 inhibits the transcriptional activity of p53.

We also generated the mutant mouse p53ΔP, which expresses a p53 that lacks the proline-rich domain, and has provided tremendous insight into p53 regulation. Studies of this mutant showed that MDM2 and MDM4 have distinct and complementary roles in p53 regulation: MDM2 mainly regulates p53 stability, whereas MDM4 regulates its activity (Fig. 1).

In addition, we have shown that MDM4 is a promising target for anti-cancer strategies, and that the combined use of MDM2 and MDM4 antagonists may reactivate p53 in some cancers. We also recently showed that the capacity of p53 to mediate transcriptional repression is important for strategies against MDM4 to work efficiently in some, but not all tumors. These studies demonstrate just how much information can be gained from studying p53 regulation in vivo, as well as the potential of such approaches for developing effective therapies.

Our group is now generating new mutant mice to pursue the analysis of p53 regulation. This approach recently helped us to demonstrate that the Mdm4-S transcript, often overexpressed in human tumors, is a marker, rather than a driver, of cancer progression. Furthermore, we showed that a nonsense mutation leading to the loss of the p53 C-terminal domain leads to increased p53 activity, and this causes bone marrow failure and pulmonary fibrosis. Importantly, the combined observation of aplastic anemia and lung fibrosis is a hallmark of syndromes caused by abnormally short telomeres. This led us to show that p53 is a major regulator of telomere metabolism, via its capacity to downregulate the expression of several key genes, including Dkc1 (Dyskerin) and Rtel1 (Fig. 2). Indeed,our team has also developped all the necessary tools to identify genes that are directly or indirectly regulated by p53.

Figure 2: Schematic diagram showing the different outcomes of a missense mutation affecting the core DNA binding domain of p53, and a nonsense mutation affecting the C-terminus.
Figure 2: Schematic diagram showing the different outcomes of a missense mutation affecting the core DNA binding domain of p53, and a nonsense mutation affecting the C-terminus.

Key publications

Year of publication 2018

(2018 May 6)

The Guardian of the Genome Revisited: p53 Downregulates Genes Required for Telomere Maintenance, DNA Repair, and Centromere Structure.

Cancers (Basel) : 10(5) : pii: E135

Year of publication 2017

Dan Filipescu, Monica Naughtin, Katrina Podsypanina, Vincent Lejour, Laurence Wilson, Zachary A Gurard-Levin, Guillermo A Orsi, Iva Simeonova, Eleonore Toufektchan, Laura D Attardi, Franck Toledo, Geneviève Almouzni (2017 Mar 31)

Essential role for centromeric factors following p53 loss and oncogenic transformation.

Genes & development : 463-480 : DOI : 10.1101/gad.290924.116

Year of publication 2016

Sara Jaber, Eléonore Toufektchan, Vincent Lejour, Boris Bardot, Franck Toledo (2016 Apr 2)

p53 downregulates the Fanconi anaemia DNA repair pathway.

Nature communications : 11091 : DOI : 10.1038/ncomms11091

Year of publication 2015

Bardot B, Bouarich-Bourimi R, Leemput J, Lejour V, Hamon A, Plancke L, Jochemsen AG, Simeonova I, Fang M, Toledo F. (2015 May 28)

Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity.

Oncogene : DOI : doi:10.1038/onc.2014.230

Year of publication 2013

Iva Simeonova, Sara Jaber, Irena Draskovic, Boris Bardot, Ming Fang, Rachida Bouarich-Bourimi, Vincent Lejour, Laure Charbonnier, Claire Soudais, Jean-Christophe Bourdon, Michel Huerre, Arturo Londono-Vallejo, Franck Toledo (2013 Feb 15)

Mutant mice lacking the p53 C-terminal domain model telomere syndromes.

Cell reports : 2046-58 : DOI : 10.1016/j.celrep.2013.05.028

Year of publication 2012

Iva Simeonova, Vincent Lejour, Boris Bardot, Rachida Bouarich-Bourimi, Aurélie Morin, Ming Fang, Laure Charbonnier, Franck Toledo (2012 Nov 23)

Fuzzy tandem repeats containing p53 response elements may define species-specific p53 target genes.

PLoS genetics : e1002731 : DOI : 10.1371/journal.pgen.1002731
All publications